SNIPR BIOME Secures €35 Million to Revolutionize CRISPR-Medicine
August 8, 2025, 9:37 pm
Location: United States, Washington, Seattle
Employees: 1001-5000
Founded date: 2000
Copenhagen's SNIPR BIOME clinched €35 million in Series B funding. This significant capital injection drives microbial CRISPR-medicine innovation. Funds target critical health challenges: developing CRISPR-Cas therapy for severe airway infections in cystic fibrosis patients, aggressively combating widespread antibiotic resistance, and pushing SNIPR001 through clinical trials for blood cancer patients to prevent bloodstream infections. The biotech firm utilizes a novel CRISPR-Cas approach. It ensures precision bacterial targeting and gene modification, preserving beneficial microbiomes. This strategic investment from new and existing backers underscores the urgent need for advanced solutions against global infectious diseases and antimicrobial resistance. It positions SNIPR BIOME at the forefront of genetic medicine.
*
Copenhagen, Denmark's SNIPR BIOME has secured a substantial €35 million in Series B funding. This crucial investment propels the biotech firm forward. It targets the development of revolutionary microbial CRISPR-medicine. The capital infusion comes from a mix of new and existing investors.
Key new investors include the Cystic Fibrosis Foundation. The German Federal Agency for Breakthrough Innovation (SPRIN-D) also joined the round. Existing partners reaffirmed their commitment. These include Lundbeckfonden BioCapital, North-East Family Office, and Wellington Partners. This funding underscores confidence in SNIPR BIOME's pioneering technology. It recognizes the urgent global need for its solutions.
SNIPR BIOME focuses its advanced CRISPR-Cas technology on critical health threats. A primary goal involves developing a CRISPR-Cas therapy. This therapy specifically targets airway infections. These infections are caused by *Pseudomonas aeruginosa*. They devastate people living with cystic fibrosis (CF). This precise intervention aims to improve patient outcomes significantly.
The company also stands at the forefront of the battle against antimicrobial resistance (AMR). AMR poses a grave global health crisis. Conventional antibiotics are failing. New approaches are desperately needed. SNIPR BIOME's technology offers a fresh paradigm. It precisely eradicates resistant bacteria. It leaves the beneficial microbial community intact. This selective action is a game-changer. It promises to restore treatment options for superbug infections.
Funds will also support critical clinical trials for SNIPR001. This investigational CRISPR therapeutic targets bloodstream infections. These infections are a severe complication for blood cancer patients. SNIPR001 is currently in a Phase 1b study. The trial unfolds across eight cancer centers in the United States. CARB-X co-funds this vital research. Success here could transform patient care. It would prevent life-threatening complications.
SNIPR BIOME’s innovation lies in its novel application of CRISPR-Cas technology. This technology offers unparalleled precision. It allows for the targeted killing of specific bacteria. It can also enable precise gene modification. The process is selective. It is rapid. It effectively removes antibiotic resistance genes. Yet, it preserves the rest of the patient’s delicate microbiome. This distinction is vital. It avoids the collateral damage often seen with broad-spectrum antibiotics.
The technology harnesses the natural bacterial CRISPR-based adaptive immune system. It programs this system. This programming targets bacteria based on their unique genomic signatures. This level of specificity marks a significant leap in genetic medicine. It enables highly focused therapeutic interventions.
Furthermore, SNIPR technology can create CRISPR-medicine. This medicine is designed to convert and produce therapeutics. It acts selectively within targeted regions. The gastrointestinal tract is a prime example. This capability opens new avenues for localized drug delivery. It enhances treatment efficacy while minimizing systemic side effects.
SNIPR BIOME boasts significant pioneering achievements. It was the first company to administer a CRISPR therapeutic orally to humans. This landmark event opened new possibilities for non-invasive treatments. The company also secured foundational patents. These US and European patents cover the use of CRISPR for targeting microbiomes. These patents solidify SNIPR BIOME's intellectual property. They reinforce its leadership position in the field.
The company actively engages in strategic collaborations. These partnerships accelerate research and development. Key collaborators include CARB-X, a global partnership fighting drug-resistant bacteria. The Gates Foundation also partners with SNIPR BIOME. This partnership targets global health challenges. The Cystic Fibrosis Foundation supports their CF research. IPATH, SPRIN-D, and MD Anderson Cancer Center further demonstrate the breadth of their collaborative network. These alliances underscore a shared commitment to addressing urgent medical needs.
This latest funding round marks a pivotal moment for SNIPR BIOME. It fuels the expansion of their infectious disease pipeline. It accelerates clinical development. The investment validates their unique position. It strengthens their role in the evolving landscape of precision medicine.
The focus on antimicrobial resistance is critical. Traditional drug pipelines are depleting. The threat of untreatable infections grows. SNIPR BIOME’s CRISPR approach offers a sustainable solution. It provides hope against superbugs. It offers new strategies for preventing and treating complex bacterial infections.
SNIPR BIOME is not just developing drugs. It is crafting a new paradigm for combating disease. Its work moves beyond broad-spectrum treatments. It embraces highly specific, genome-guided interventions. This precision can minimize side effects. It maximizes therapeutic impact.
The company, founded in 2011, continues to innovate. It transforms the promise of CRISPR technology into tangible patient benefits. The new capital will expedite this transformation. It positions SNIPR BIOME as a key player. It shapes the future of microbial CRISPR-medicine. This is a monumental step forward for global health.
*
Danish Biotech Secures Major Capital for CRISPR Innovation
Copenhagen, Denmark's SNIPR BIOME has secured a substantial €35 million in Series B funding. This crucial investment propels the biotech firm forward. It targets the development of revolutionary microbial CRISPR-medicine. The capital infusion comes from a mix of new and existing investors.
Key new investors include the Cystic Fibrosis Foundation. The German Federal Agency for Breakthrough Innovation (SPRIN-D) also joined the round. Existing partners reaffirmed their commitment. These include Lundbeckfonden BioCapital, North-East Family Office, and Wellington Partners. This funding underscores confidence in SNIPR BIOME's pioneering technology. It recognizes the urgent global need for its solutions.
Targeting Critical Infections and Antimicrobial Resistance
SNIPR BIOME focuses its advanced CRISPR-Cas technology on critical health threats. A primary goal involves developing a CRISPR-Cas therapy. This therapy specifically targets airway infections. These infections are caused by *Pseudomonas aeruginosa*. They devastate people living with cystic fibrosis (CF). This precise intervention aims to improve patient outcomes significantly.
The company also stands at the forefront of the battle against antimicrobial resistance (AMR). AMR poses a grave global health crisis. Conventional antibiotics are failing. New approaches are desperately needed. SNIPR BIOME's technology offers a fresh paradigm. It precisely eradicates resistant bacteria. It leaves the beneficial microbial community intact. This selective action is a game-changer. It promises to restore treatment options for superbug infections.
Funds will also support critical clinical trials for SNIPR001. This investigational CRISPR therapeutic targets bloodstream infections. These infections are a severe complication for blood cancer patients. SNIPR001 is currently in a Phase 1b study. The trial unfolds across eight cancer centers in the United States. CARB-X co-funds this vital research. Success here could transform patient care. It would prevent life-threatening complications.
The Power of Precision CRISPR Technology
SNIPR BIOME’s innovation lies in its novel application of CRISPR-Cas technology. This technology offers unparalleled precision. It allows for the targeted killing of specific bacteria. It can also enable precise gene modification. The process is selective. It is rapid. It effectively removes antibiotic resistance genes. Yet, it preserves the rest of the patient’s delicate microbiome. This distinction is vital. It avoids the collateral damage often seen with broad-spectrum antibiotics.
The technology harnesses the natural bacterial CRISPR-based adaptive immune system. It programs this system. This programming targets bacteria based on their unique genomic signatures. This level of specificity marks a significant leap in genetic medicine. It enables highly focused therapeutic interventions.
Furthermore, SNIPR technology can create CRISPR-medicine. This medicine is designed to convert and produce therapeutics. It acts selectively within targeted regions. The gastrointestinal tract is a prime example. This capability opens new avenues for localized drug delivery. It enhances treatment efficacy while minimizing systemic side effects.
Pioneering Achievements and Global Collaborations
SNIPR BIOME boasts significant pioneering achievements. It was the first company to administer a CRISPR therapeutic orally to humans. This landmark event opened new possibilities for non-invasive treatments. The company also secured foundational patents. These US and European patents cover the use of CRISPR for targeting microbiomes. These patents solidify SNIPR BIOME's intellectual property. They reinforce its leadership position in the field.
The company actively engages in strategic collaborations. These partnerships accelerate research and development. Key collaborators include CARB-X, a global partnership fighting drug-resistant bacteria. The Gates Foundation also partners with SNIPR BIOME. This partnership targets global health challenges. The Cystic Fibrosis Foundation supports their CF research. IPATH, SPRIN-D, and MD Anderson Cancer Center further demonstrate the breadth of their collaborative network. These alliances underscore a shared commitment to addressing urgent medical needs.
The Future of Precision Medicine
This latest funding round marks a pivotal moment for SNIPR BIOME. It fuels the expansion of their infectious disease pipeline. It accelerates clinical development. The investment validates their unique position. It strengthens their role in the evolving landscape of precision medicine.
The focus on antimicrobial resistance is critical. Traditional drug pipelines are depleting. The threat of untreatable infections grows. SNIPR BIOME’s CRISPR approach offers a sustainable solution. It provides hope against superbugs. It offers new strategies for preventing and treating complex bacterial infections.
SNIPR BIOME is not just developing drugs. It is crafting a new paradigm for combating disease. Its work moves beyond broad-spectrum treatments. It embraces highly specific, genome-guided interventions. This precision can minimize side effects. It maximizes therapeutic impact.
The company, founded in 2011, continues to innovate. It transforms the promise of CRISPR technology into tangible patient benefits. The new capital will expedite this transformation. It positions SNIPR BIOME as a key player. It shapes the future of microbial CRISPR-medicine. This is a monumental step forward for global health.